Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (25)	2/14/2002 10:08:31 AM
From: nigel bates	Read Replies (1) \| Respond to of 510

Ciphergen Signs CRADA With the NIAID for AIDS Research FREMONT, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - news) announced today that it has signed a Collaborative Research and Development Agreement (CRADA) with the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases. The CRADA will focus on ``The Discovery and Characterization of Novel Non-cytolytic Antiviral Factors Derived from CD8+ T Cells of HIV-Infected Individuals.'' The CRADA contains a detailed research work plan with significant scientific contributions from both parties and specifies procedures for licensing and commercialization of discoveries with therapeutic or diagnostic product potential. Understanding the factors that contribute to the suppression of HIV replication in infected individuals is of great importance for the development of preventive and therapeutic strategies. Recently, investigators in the Laboratory of Immunoregulation, NIAID, have demonstrated that non-cytolytic antiviral activities are present in certain HIV-infected patients. The identity of the factor(s) remains unknown. The identification and characterization of novel CD8+ T-cell-derived antiviral factor(s) could have significant implications for the development of therapeutic strategies and advancing the understanding of HIV pathogenesis, which is a multifactorial and multiphasic process. The NIAID and Ciphergen will work closely together in this CRADA to facilitate the discovery and characterization of CD8 - cell-derived antiviral factors, using Ciphergen's ProteinChip® Biomarker System as an enabling technology. ``We're delighted to be undertaking this project with researchers at NIAID, given the enormous potential medical benefits that could derive from this research,'' stated William E. Rich, President and CEO of Ciphergen. ``Our ProteinChip technology is well established for differential protein expression as a means of discovering medically relevant proteins, and is currently being employed by several leading research groups in the fight against AIDS.''...